RecruitingPhase 2NCT06711705

Elranatamab in Relapsed/Refractory Multiple Myeloma

Phase II MRD-Adapted Study of Elranatamab in Relapsed/Refractory

Sponsor

University of California, San Diego

Enrollment

33 participants

Start Date

Dec 18, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

This study evaluates the efficacy of elranatamab alone in patients with relapsed and/or refractory Multiple myeloma who has previously received 1 to 3 combinations of treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests elranatamab — a bispecific antibody that directs the immune system to attack myeloma cells — in patients with multiple myeloma that has returned or stopped responding to treatment. **You may be eligible if...** - You have multiple myeloma that has relapsed or is no longer responding to treatment - You have received 1 to 3 prior lines of therapy that included an anti-CD38 antibody (like daratumumab), a proteasome inhibitor, an immunomodulatory drug, and ideally a BCMA-targeted CAR T-cell therapy - If you have not received CAR T-cell therapy, you must be ineligible for it or have chosen to defer it **You may NOT be eligible if...** - You have not received the required prior therapies - Your myeloma has not relapsed or become refractory - You are currently eligible for and willing to pursue CAR T-cell therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGElranatamab

Subcutaneous injection of elranatamab. If patient achieves MRD negative remission, patient would enter treatment-free observation period with MRD monitoring.